<DOC>
	<DOCNO>NCT01666171</DOCNO>
	<brief_summary>RATIONALE : Learning effect metformin hydrochloride breast density woman early-stage breast cancer may help plan treatment . PURPOSE : This trial study change breast density patient early-stage breast cancer treat metformin hydrochloride placebo CAN-NCIC-MA.32 .</brief_summary>
	<brief_title>Studying Changes Breast Density Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride Placebo CAN-NCIC-MA.32</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate change percent mammographic density contralateral ( unaffected breast ) prior initiation metformin hydrochloride ( metformin ) placebo treatment one year therapy patient hormone receptor-negative breast cancer ( i.e. , endocrine therapy ) . Secondary - To evaluate change percent breast density contralateral ( unaffected breast ) prior initiation metformin placebo treatment two year therapy patient hormone receptor-negative breast cancer ( i.e. , endocrine therapy ) . - To evaluate whether baseline mammographic density correlate baseline fast plasma insulin , glucose level , Homeostasis Model Assessment ( HOMA ) ( collect treatment protocol CAN-NCIC-MA.32 ) ( MA.32 ) . - To evaluate whether change dense area response metformin therapy pre-treatment two year therapy correlate change fast plasma insulin , glucose level , HOMA ( collect treatment protocol MA.32 ) time period . - To explore whether change mammographic density woman metformin associate risk second primary breast cancer . OUTLINE : Patients ' mammogram take baseline approximately 1 2 year metformin placebo treatment retrieve analyzed breast-density change . Pre-menopausal patient ' menstrual cycle information also collect baseline every 6 month 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients must either concurrently enrol previously enrol Canada ( CAN ) National Cancer Institute Canada ( NCIC ) study MA.32 ( CANNCICMA.32 ) ( MA.32 ) ; eligible patient may either pre postmenopausal Patients must hormone receptornegative breast cancer Patients must breast density â‰¥ 25 % ( correlate Breast ImagingReporting Data [ BIRAD ] 2 category `` scatter fibroglandular density '' great ) Baseline digital mammogram take within 12 month prior registration MA.32 , least craniocaudal ( CC ) view use enrollment MA.32 must available submission ; patient previously enrol MA.32 one year elapse baseline mammogram , oneyear mammogram must also available submission Contralateral unaffected breast place ( prior cancer radiation , implant , plan breast surgery contralateral breast course study ) ; woman prior biopsy unaffected breast eligible PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics Women receive endocrine therapy ( e.g. , tamoxifen , aromatase inhibitor ) eligible</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>